Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications

Area of Science:

• Systems biology
• Molecular oncology
• Biomarker discovery

Background:

• Genomics and proteomics offer advanced insights into thyroid tumor markers (TTM).
• Understanding molecular alterations is crucial for thyroid cancer pathogenesis and targeted therapies.

Purpose of the Study:

• To review the application of genomics and proteomics in optimizing thyroid tumor marker (TTM) utilization.
• To discuss the potential and challenges of integrating these systems biology approaches into clinical practice.

Main Methods:

• Tissue microarray studies for genetic mapping and proteomic profiling of TTM.
• Analysis of genetic mutations (RAS, RET, BRAF) and gene fusions (PAX 8, PPAR-gamma) in thyroid cancers.
• Proteomic analysis to understand the state of thyroid cancer cells.

Main Results:

• Specific genetic mutations are associated with papillary and medullary thyroid cancers.
• Gene fusions are identified in follicular thyroid cancers.
• Proteomic data provides insights into cancer cell molecular states.

Conclusions:

• Genomic and proteomic analyses can clarify thyroid cancer pathogenesis and guide targeted therapies.
• Obstacles to routine TTM use include interpretation issues, standardization, and cost.
• Large needle aspiration biopsy (LNAB) techniques may improve diagnostic accuracy, as seen with galectin-3.